{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:07:55Z","timestamp":1786118875240,"version":"build-2736575974"},"reference-count":65,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1097\/cji.0b013e31815c5153","type":"journal-article","created":{"date-parts":[[2008,2,5]],"date-time":"2008-02-05T03:00:58Z","timestamp":1202180458000},"page":"166-179","source":"Crossref","is-referenced-by-count":36,"title":["In Vivo Tracking of Dendritic Cells in Patients With Multiple Myeloma"],"prefix":"10.1097","volume":"31","author":[{"given":"H. Miles","family":"Prince","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic M.","family":"Wall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Honemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Harrrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Quach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mick","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddie","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Davison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Loudovaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jude","family":"Moloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Loveland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Bartholeyns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Katsifis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Mileshkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210227","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/j.1445-5994.2006.01218.x","article-title":"Current status of new drugs for the treatment of patients with multiple myeloma","volume":"36","author":"Kenealy","year":"2006","journal-title":"Intern Med J"},{"key":"R2-6-20210227","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1586\/14737140.6.12.1769","article-title":"Immunotherapy of multiple myeloma: the start of a long and tortuous journey","volume":"6","author":"Harrison","year":"2006","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"R3-6-20210227","first-page":"5277a","article-title":"Intranodal vaccination with idiotype-pulsed dendritic cells induces potent and long-lasting cellular and humoral immune responses in myeloma patients. (abstract)","volume":"102","author":"Yi","year":"2003","journal-title":"Blood"},{"key":"R4-6-20210227","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood.V93.7.2411","article-title":"Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for Multiple Myeloma-A Feasibility Study","volume":"93","author":"Reichardt","year":"1999","journal-title":"Blood"},{"key":"R5-6-20210227","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1083-8791(00)70027-9","article-title":"Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma","volume":"6","author":"Liso","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"key":"R6-6-20210227","first-page":"1139","article-title":"Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells","volume":"88","author":"Reichardt","year":"2003","journal-title":"Haematologica"},{"key":"R7-6-20210227","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.bbmt.2005.09.003","article-title":"Dendritic cell immunotherapy for the treatment of neoplastic disease","volume":"12","author":"Decker","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"R8-6-20210227","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/(SICI)1097-0215(19991008)83:2<215::AID-IJC12>3.0.CO;2-Q","article-title":"Idiotypic protein pulsed dendritic cell vaccination in multiple myeloma","volume":"83","author":"Lim","year":"1999","journal-title":"Int J Cancer"},{"key":"R9-6-20210227","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1182\/blood.V89.9.3129","article-title":"Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma\u2014long-term results of a clinical trial","volume":"89","author":"Hsu","year":"1997","journal-title":"Blood"},{"key":"R10-6-20210227","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1182\/blood-2004-09-3707","article-title":"NY-ESO-1 is highly expressed in poor prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses","volume":"105","author":"Van Rhee","year":"2005","journal-title":"Blood"},{"key":"R11-6-20210227","first-page":"9","article-title":"Expression of cacer\/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies in heterogeneous and correlates with site, stage and risk status disease","volume":"3","author":"Dhodapkar","year":"2003","journal-title":"Cancer Immun"},{"key":"R12-6-20210227","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/01.cji.0000175685.36239.e5","article-title":"SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs","volume":"28","author":"Taylor","year":"2005","journal-title":"J Immunother"},{"key":"R13-6-20210227","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1182\/blood-2006-04-014621","article-title":"PASD1 is a potential multiple myeloma-associated antigen","volume":"108","author":"Sahota","year":"2006","journal-title":"Blood"},{"key":"R14-6-20210227","doi-asserted-by":"crossref","first-page":"13885","DOI":"10.1073\/pnas.0405884101","article-title":"Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression","volume":"101","author":"Oka","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"R15-6-20210227","doi-asserted-by":"crossref","first-page":"6935","DOI":"10.4049\/jimmunol.176.11.6935","article-title":"Identification of HLA-A*0201-presented T cell epitopes derived from the oncofetal antigen-immature laminin receptor protein in patients with hematological malignancies","volume":"176","author":"Siegel","year":"2006","journal-title":"J Immunol"},{"key":"R16-6-20210227","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1182\/blood.V106.11.2781.2781","article-title":"RHAMM\/CD168-R3 Peptide vaccination of HAL-A2+ patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and multiple myeloma (MM) (abstract)","volume":"106","author":"Greiner","year":"2005","journal-title":"Blood"},{"key":"R17-6-20210227","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-04-0650","article-title":"Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24","volume":"11","author":"Rew","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R18-6-20210227","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1158\/1078-0432.CCR-04-0825","article-title":"Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes","volume":"10","author":"Azuma","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R19-6-20210227","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s002620050315","article-title":"Making the most of mucin: a novel target for tumor immunotherapy","volume":"43","author":"Barratt-Boyes","year":"1996","journal-title":"Cancer Immunol Immunother"},{"key":"R20-6-20210227","first-page":"5227","article-title":"MUC1-reactive cytotoxic memory T cells in bone marrow of multiple myeloma patients (abstract)","volume":"102","author":"Beckhove","year":"2003","journal-title":"Blood"},{"issue":"3","key":"R21-6-20210227","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1158\/1078-0432.CCR-05-1574","article-title":"Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma","volume":"12","author":"Loveland","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R22-6-20210227","doi-asserted-by":"crossref","first-page":"R27","DOI":"10.1186\/bcr1505","article-title":"Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]","volume":"8","author":"Apostolopoulos","year":"2006","journal-title":"Breast Cancer Res"},{"key":"R23-6-20210227","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood.V96.9.3147.h8003147_3147_3153","article-title":"Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma","volume":"96","author":"Treon","year":"2000","journal-title":"Blood"},{"key":"R24-6-20210227","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1182\/blood.V93.4.1287","article-title":"Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone","volume":"93","author":"Treon","year":"1999","journal-title":"Blood"},{"key":"R25-6-20210227","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.4049\/jimmunol.153.5.2102","article-title":"Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient","volume":"153","author":"Takahashi","year":"1994","journal-title":"J Immunol"},{"key":"R26-6-20210227","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1046\/j.1365-2141.2003.04677.x","article-title":"Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide","volume":"123","author":"Mileshkin","year":"2003","journal-title":"Br J Haematol"},{"key":"R27-6-20210227","doi-asserted-by":"crossref","first-page":"10128","DOI":"10.1073\/pnas.92.22.10128","article-title":"Oxidative\/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses","volume":"92","author":"Apostolopoulos","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"R28-6-20210227","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ijc.1323","article-title":"A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection","volume":"93","author":"Jonuleit","year":"2001","journal-title":"Int J Cancer"},{"key":"R29-6-20210227","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.193.2.233","article-title":"Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells","volume":"193","author":"Dhodapkar","year":"2001","journal-title":"J Exp Med"},{"key":"R30-6-20210227","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1146\/annurev.immunol.21.120601.141040","article-title":"Tolerogenic dendritic cells","volume":"21","author":"Steinman","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"R31-6-20210227","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00262-003-0429-0","article-title":"Phase I\/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma","volume":"53","author":"Hersey","year":"2004","journal-title":"Cancer Immunol Immunother"},{"key":"R32-6-20210227","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1182\/blood-2004-10-3991","article-title":"Efficient migration of dendritic cells toward lymph node chemokines and induction of T(H)1 responses require maturation stimulus and apoptotic cell interaction","volume":"106","author":"Bertho","year":"2005","journal-title":"Blood"},{"key":"R33-6-20210227","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/sj.leu.2401888","article-title":"Differentiation of antigen-presenting cells (dendritic cells and macrophages) for therapeutic application in patients with lymphoma","volume":"14","author":"Chaperot","year":"2000","journal-title":"Leukemia"},{"key":"R35-6-20210227","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1158\/1078-0432.CCR-06-1879","article-title":"Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients","volume":"12","author":"Lesimple","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R36-6-20210227","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00259-005-1825-9","article-title":"Biodistribution of radiolabelled human dendritic cells injected by various routes","volume":"32","author":"Quillien","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R37-6-20210227","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00262-006-0181-3","article-title":"In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian carcinoma","volume":"56","author":"Ritchie","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"R38-6-20210227","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1161\/01.CIR.0000163546.27639.AA","article-title":"Monitoring of bone marrow cell homing into the infarcted human myocardium","volume":"111","author":"Hofmann","year":"2005","journal-title":"Circulation"},{"key":"R39-6-20210227","first-page":"1989","article-title":"Copper-62-labeled pyruvaldehyde bis(N4-methylthiosemicarbazonato)copper(II): synthesis and evaluation as a positron emission tomography tracer for cerebral and myocardial perfusion","volume":"31","author":"Green","year":"1990","journal-title":"J Nucl Med"},{"key":"R40-6-20210227","first-page":"684","article-title":"The kinetics of copper-62-PTSM in the normal human heart","volume":"33","author":"Beanlands","year":"1992","journal-title":"J Nucl Med"},{"key":"R41-6-20210227","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03165001","article-title":"Differential mechanism of retention of Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) (Cu-PTSM) by brain and tumor: a novel radiopharmaceutical for positron emission tomography imaging","volume":"9","author":"Fujibayashi","year":"1995","journal-title":"Ann Nucl Med"},{"key":"R42-6-20210227","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/0883-2897(92)90104-7","article-title":"Subcellular distribution of tissue radiocopper following intravenous administration of 67Cu-labeled Cu-PTSM","volume":"19","author":"Baerga","year":"1992","journal-title":"Int J Rad Appl Instrum B"},{"key":"R43-6-20210227","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/immu.200390019","article-title":"Naive CD8+ T cell recruitment and proliferation are dependent on stage of dendritic cell maturation","volume":"33","author":"Kaiser","year":"2003","journal-title":"Eur J Immunol"},{"key":"R44-6-20210227","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s00259-002-1001-4","article-title":"111In-oxine and 99mTc-HMPAO labelling of antigen-loaded dendritic cells: in vivo imaging and influence on motility and actin content","volume":"30","author":"Blocklet","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R45-6-20210227","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1479-5876-2-27","article-title":"Evaluation of in vivo labelled dendritic cell migration in cancer patients","volume":"2","author":"Ridolfi","year":"2004","journal-title":"J Transl Med"},{"key":"R46-6-20210227","first-page":"12","article-title":"Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state","volume":"63","author":"De Vries","year":"2003","journal-title":"Cancer Res"},{"key":"R47-6-20210227","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s002620050555","article-title":"Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells","volume":"48","author":"Mackensen","year":"1999","journal-title":"Cancer Immunol Immunother"},{"key":"R48-6-20210227","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/00008390-199910000-00007","article-title":"Immature human monocyte-derived dendritic cells migrate rapidly to draining lymph nodes after intradermal injection for melanoma immunotherapy","volume":"9","author":"Thomas","year":"1999","journal-title":"Melanoma Res"},{"key":"R49-6-20210227","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00259-005-1858-0","article-title":"The role of molecular imaging in the development of dendritic cell-based cancer vaccines","volume":"32","author":"Lucignani","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R50-6-20210227","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1200\/JCO.2003.04.042","article-title":"Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients","volume":"21","author":"Bedrosian","year":"2003","journal-title":"J Clin Oncol"},{"key":"R51-6-20210227","first-page":"1","article-title":"Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer","author":"Dohnal","year":"2007","journal-title":"Cytotherapy"},{"key":"R52-6-20210227","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1200\/JCO.2003.02.135","article-title":"Dendritic cell-based vaccination in solid cancer","volume":"21","author":"Stift","year":"2003","journal-title":"J Clin Oncol"},{"key":"R53-6-20210227","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/(SICI)1097-0045(19980615)36:1<39::AID-PROS6>3.0.CO;2-6","article-title":"Evaluation of phase I\/II clinical trials in prostate cancer with dendritic cells and PSMA peptides","volume":"36","author":"Tjoa","year":"1998","journal-title":"Prostate"},{"key":"R54-6-20210227","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/nm0196-52","article-title":"Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells","volume":"2","author":"Hsu","year":"1996","journal-title":"Nat Med"},{"key":"R55-6-20210227","doi-asserted-by":"crossref","first-page":"8809","DOI":"10.1073\/pnas.141226398","article-title":"Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy","volume":"98","author":"Fong","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"R56-6-20210227","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.4049\/jimmunol.166.6.4254","article-title":"Dendritic cells injected via different routes induce immunity in cancer patients","volume":"166","author":"Fong","year":"2001","journal-title":"J Immunol"},{"key":"R57-6-20210227","first-page":"56","article-title":"Migration of human dendritic cells after injection in patients with metastatic malignancies","volume":"59","author":"Morse","year":"1999","journal-title":"Cancer Res"},{"key":"R58-6-20210227","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/nri1222","article-title":"Homing and cellular traffic in lymph nodes","volume":"3","author":"von Andrian","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"R59-6-20210227","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1084\/jem.20030448","article-title":"Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming","volume":"198","author":"MartIn-Fontecha","year":"2003","journal-title":"J Exp Med"},{"key":"R60-6-20210227","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1084\/jem.188.2.373","article-title":"Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites","volume":"188","author":"Dieu","year":"1998","journal-title":"J Exp Med"},{"key":"R61-6-20210227","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1002\/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N","article-title":"Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation","volume":"28","author":"Sallusto","year":"1998","journal-title":"Eur J Immunol"},{"key":"R62-6-20210227","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.4049\/jimmunol.164.5.2487","article-title":"Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cell-based vaccines","volume":"164","author":"Barratt-Boyes","year":"2000","journal-title":"J Immunol"},{"key":"R63-6-20210227","first-page":"1654","article-title":"Heterogeneous expression of the SSX cancer\/testis antigens in human melanoma lesions and cell lines","volume":"60","author":"dos Santos","year":"2000","journal-title":"Cancer Res"},{"key":"R64-6-20210227","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1054\/bjoc.2000.1291","article-title":"Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours","volume":"83","author":"Jungbluth","year":"2000","journal-title":"Br J Cancer"},{"key":"R65-6-20210227","doi-asserted-by":"crossref","first-page":"9167","DOI":"10.1158\/0008-5472.CAN-04-1442","article-title":"Intratumor heterogeneity of cancer\/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2\u2032-deoxycytidine","volume":"64","author":"Sigalotti","year":"2004","journal-title":"Cancer Res"},{"issue":"3","key":"R66-6-20210227","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/annonc\/11.suppl_3.199","article-title":"Dendritic cell-based immunotherapy of cancer","volume":"11","author":"Zitvogel","year":"2000","journal-title":"Ann Oncol"}],"container-title":["Journal of Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CJI.0b013e31815c5153","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:01:06Z","timestamp":1786035666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002371-200802000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/cji.0b013e31815c5153","relation":{},"ISSN":["1524-9557"],"issn-type":[{"value":"1524-9557","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}